The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 177-page report you will receive 100 charts– all unavailable elsewhere.
The 177-page report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Asthma & COPD Therapies Market forecasts from 2020-2030
• Profiles of the leading 26 asthma & COPD companies:
• Adamis Pharmaceuticals Corporation
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Dimerix
• GlaxoSmithKline
• Innoviva
• Lallemand Pharma International
• Merck
• Mereo BioPharma Group plc
• MundiPharma
• Novartis
• Pulmatrix
• Respiratorius AB
• Roche
• Other companies
• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2020-2030
• Recent developments
• Future Outlook
• This report discusses factors that drive and restrain the asthma and COPD market.
• Key questions answered by this report:
• How is the Asthma & COPD Companies market evolving?
• What is driving and restraining the Asthma & COPD Companies market?
• What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
• What will be the main driver for the overall market from 2019 to 2030?
• Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry evolve during the period between 2019 and 2030?
Visiongain’s study is intended for anyone requiring commercial analyses for the top 26 asthma & COPD therapies companies. You find data, trends and predictions.
Buy our report today Pharma Leader Series: Top 26 Asthma & COPD Companies: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Report Overview
1.1 Global Asthma & COPD Companies Market Overview
1.2 Global Asthma & COPD Companies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Introduction to Asthma & COPD Therapies
2.1 COPD Overview
2.1.1 Chronic Obstructive Pulmonary Disease Medications
2.1.1.1 Bronchodilators
2.1.1.2 Glucocorticoids
2.2 Asthma Overview
2.2.1 Desirable inhaler characteristics for treating asthma
2.3 Asthma & COPD Respiratory Inhalers Overview
2.3.1 Nebulizers
2.3.2 Metered Dose Inhaler
2.3.3 Breath-Actuated Pressurised Metered-Dose Inhalers
2.3.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices
2.3.5 Dry powder inhalers (DPIs)
2.3.6 Soft Mist Inhalers
2.4 Asthma & COPD Therapies – Realising Their Potential, Market Drivers
2.4.1 Combination Therapies - Asthma & COPD Products
2.4.1.1 LAMA/LABA Combinations
2.4.1.2 LABA/LCS Combination
2.4.1.3 LABA+LAMA Vs. LABA+ICS Combinations
2.4.2 Triple Combination – Asthma & COPD Products
2.4.2.1.1 LAMA/LABA/ICS “Triple Combination Inhalers”
2.4.3 Opportunities in Telehealth
2.5 Market Restraints
2.6 Asthma & COPD Products: Trends and Developments
2.6.1 E-Technology in Asthma and COPD
3 Leading Asthma & COPD Companies: Overview, 2019
3.1 The Global Asthma & COPD Companies Market In 2019
3.2 Leading Companies in the Asthma & COPD Market, 2020
3.3 How Will Leading Companies’ Market Shares Change To 2030?
4 Leading Asthma & COPD Companies Worldwide, 2020
4.1 Astrazeneca – Company Overview & Analysis
4.1.1 Astrazeneca Marketed Asthma & COPD Products
4.1.1.1 Latest Developments Related to Key Marketed Products
4.1.1.1.1 Symbicort: Recent Developments
4.1.1.1.2 Bevespi Aerosphere: Recent Developments
4.1.1.1.3 Tudorza/ Eklira Genuair: Recent Developments
4.1.1.1.4 Duaklir: Recent Developments
4.1.1.1.5 Fasenra: Recent Developments
4.1.1.1.6 Other Recent Developments
4.1.2 Astrazeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.1.2.1 Latest Developments Related to Key Pipeline Products
4.1.2.1.1 Pt010/ Pt009/ Pt008/ Pt005: Pipeline Developments
4.1.2.1.2 Fasenra: Pipeline Developments
4.1.2.1.3 Tezepelumab: Pipeline Developments
4.1.2.1.4 Tralokinumab: Pipeline Developments
4.1.3 Astrazeneca -Asthma & COPD Market Forecast, 2019-2030
4.2 Glaxosmithkline – Company Overview & Analysis
4.2.1 Glaxosmithkline Marketed Asthma & COPD Products
4.2.1.1 Latest Developments Related to Key Marketed Products
4.2.1.1.1 Relvar/Breo Ellipta: Recent Developments
4.2.1.1.2 Anoro Ellipta: Recent Developments
4.2.1.1.3 Nucala: Recent Developments
4.2.1.1.4 Seretide/Advair: Recent Developments
4.2.1.1.5 Trelegy Ellipta: Recent Developments
4.2.1.1.6 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments
4.2.2 Glaxosmithkline, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.2.2.1 Latest Developments Related to Key Pipeline Products
4.2.2.1.1 Nucala: Recent Developments
4.2.3 Glaxosmithkline -Asthma & COPD Market Forecast, 2019-2030
4.3 Boehringer Ingelheim – Company Overview & Analysis
4.3.1 Boehringer Ingelheim Marketed Asthma & COPD Products
4.3.1.1 Latest Developments Related to Key Marketed Products
4.3.1.1.1 Spiriva Respimat: Recent Developments
4.3.1.1.1 Spiolto Respimat: Recent Developments
4.3.1.1.2 Ofev: Recent Developments
4.3.2 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.3.3 Boehringer Ingelheim -Asthma & COPD Market Forecast, 2019-2030
4.4 Teva – Company Overview & Analysis
4.4.1 Teva Marketed Asthma & COPD Products
4.4.1.1 Latest Developments Related to Key Marketed Products
4.4.1.1.1 Qvar: Recent Developments
4.4.1.1.2 Proair HFA: Recent Development
4.4.1.1.3 : Duoresp Spiromax: Recent Developments
4.4.1.1.4 Aerivio Spiromax: Recent Developments
4.4.1.1.5 Cinqair/Cinqaero: Recent Developments
4.4.1.1.6 Airduo Respiclick / Armonair Respiclick: Recent Development
4.4.2 Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.4.2.1 Latest Developments Related to Key Pipeline Products
4.4.2.1.1 Proair E-Respiclick: Recent Developments
4.4.3 Teva -Asthma & COPD Market Forecast, 2019-2030
4.5 Merck – Company Overview & Analysis
4.5.1 Merck Marketed Asthma & COPD Products
4.5.1.1 Latest Developments Related to Key Marketed Products
4.5.1.1.1 Dulera: Recent Development
4.5.2 Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.5.3 Merck -Asthma & COPD Market Forecast, 2019-2030
4.6 Roche – Company Overview & Analysis
4.6.1 Roche Marketed Asthma & COPD Products
4.6.1.1 Latest Developments Related to Key Marketed Products
4.6.1.1.1 Xolair: Recent Developments
4.6.2 Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.6.2.1 Latest Developments Related to Key Pipeline Products
4.6.2.1.1 Rg3637: Pipeline Developments
4.6.3 Roche -Asthma & COPD Market Forecast, 2019-2030
4.7 Novartis – Company Overview & Analysis
4.7.1 Novartis Marketed Asthma & COPD Products
4.7.1.1 Latest Developments Related to Key Marketed Products
4.7.1.1.1 Ultibro Breezhaler: Recent Developments
4.7.1.1.2 Xolair: Recent Developments
4.7.2 Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.7.2.1 Latest Developments Related to Key Pipeline Products
4.7.2.1.1 Qaw039: Pipeline Developments
4.7.2.1.2 Qbw251: Pipeline Developments
4.7.2.1.3 Qvm149: Pipeline Developments
4.7.2.1.4 Csj117: Pipeline Developments
4.7.2.1.5 Cjm112: Pipeline Developments
4.7.3 Novartis -Asthma & COPD Market Forecast, 2019-2030
4.8 Regeneron Pharmaceuticals (Sanofi)– Company Overview & Analysis
4.8.1 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook
4.8.1.1 Latest Developments Related to Key Pipeline Products
4.8.1.1.1 Dupilimab/ Dupixent/Sar23189: Pipeline Developments
4.8.1.1.2 Sar440340: Pipeline Developments
4.8.2 Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2019-2030
4.9 Mundipharma – Company Overview & Analysis
4.9.1 Mundipharma Marketed Asthma & COPD Products
4.9.1.1 Latest Developments Related to Key Marketed Products
4.9.1.1.1 Flutiform (Fluticasone Propionate and Formoterol): Recent Developments
4.9.1.1.2 Company Related Developments
4.9.2 Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.9.2.1 Latest Developments Related to Key Pipeline Products
4.9.2.1.1 Flutiform K-Haler (Fluticasone Propionate and Formoterol): Recent Developments
4.10 Theravance Biopharma – Company Overview & Analysis
4.10.1 Theravance Biopharma Marketed Asthma & COPD Products
4.10.1.1 Latest Developments Related to Key Marketed Products
4.10.1.1.1 Trelegy Ellipta: Recent Developments
4.10.2 Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.10.2.1 Latest Developments Related to Key Pipeline Products
4.10.2.1.1 Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA): Recent Developments
4.10.2.2 Revefenacin (Td-4208): Recent Developments
4.11 Amphastar Pharmaceuticals – Company Overview & Analysis
4.11.1 Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.11.1.1 Latest Developments Related to Key Pipeline Products
4.11.1.1.1 Primatene Mist HFA: Recent Developments
4.11.1.1.2 Albuterol Dpi: Recent Developments
4.12 Cipla– Company Overview & Analysis
4.12.1 Cipla Marketed Asthma & COPD Products
4.12.1.1 Latest Developments Related to Key Marketed Products
4.12.1.1.1 Budesonide Inhalation Suspension: Pipeline Developments
4.12.1.1.2 Synchrobreathe: Pipeline Developments
4.12.1.2 Cipla Launch Plans for Respiratory Products
4.13 Sunovion Pharmaceuticals– Company Overview & Analysis
4.13.1 Sunovion Pharmaceuticals: Marketed Asthma & COPD Products
4.13.1.1 Latest Developments Related to Key Marketed Products
4.13.1.1.1 Sun-101: Recent Developments
4.13.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.13.3 Sunovion -Asthma & COPD Market Forecast, 2019-2030
4.14 Aerocrine (Circassia)– Company Overview & Analysis
4.14.1 Circassia Marketed Asthma & COPD Products
4.14.1.1 Latest Developments Related to Key Marketed Products
4.14.1.1.1 Niox: Recent Developments
4.14.1.1.2 Tudorza Pressair: Recent Developments
4.14.2 Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.14.2.1 Latest Developments Related to Key Pipeline Products
4.14.2.1.1 Duaklir Pressair Us: Pipeline Developments
4.14.3 Circassia -Asthma & COPD Market Forecast, 2019-2030
4.15 Vectura Group – Company Overview & Analysis
4.15.1 Vectura Group Marketed Asthma & COPD Products
4.15.1.1 Latest Developments Related to The Marketed Products
4.15.1.1.1 Flutiform (Mundipharma, Europe And Rest of World (Excl. North America)/Kyorin, Japan): Recent Developments
4.15.1.1.2 Ultibro Breezhaler, Seebri Breezhaler Utibron Neohaler Inhalation Powder and Seebri Neohaler (Novartis/Sunovion, US): Recent Developments
4.15.1.1.3 GSK Ellipta Products: Recent Developments
4.15.1.1.4 Airflusal Forspiro (Sandoz, Eu & Row): Recent Developments
4.15.1.1.5 Breelibtm (Bayer, Eu & Row Excluding Us): Recent Developments
4.15.2 Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.15.2.1 Latest Developments Related to The Pipeline Products
4.15.2.1.1 Vr647 (Paediatric Asthma Us): Recent Developments
4.15.2.1.2 Vr475 (Severe Adult Asthma Eu): Recent Developments
4.15.2.1.3 Vr315 (Hikma, Us): Recent Developments
4.15.2.1.4 Vr632 (Sandoz, Eu): Recent Developments
4.15.2.1.5 Vr410 (Pulmatrix, Us): Recent Developments
4.15.2.1.6 Qvm149 (Novartis: Europe & Row): Recent Developments
4.15.2.1.7 Key Outlook For 2018-2019
4.15.3 Vectura Group -Asthma & COPD Market Forecast, 2019-2030
4.16 Lallemand Pharma Ag– Company Overview & Analysis
4.16.1 Lallemand Pharma Ag Marketed Asthma & COPD Products
4.16.1.1 Latest Development Related to The Marketed Products
4.16.1.1.1 PMBL: Recent Developments
4.16.2 Lallemand Pharma Ag, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.16.3 Lallemand Pharma -Asthma & COPD Market Forecast, 2019-2030
4.17 Chiesi Farmaceutici S.P.A. – Company Overview & Analysis
4.17.1 Chiesi Farmaceutici S.P.A Marketed Asthma & COPD Products
4.17.1.1 Latest Developments Related to Key Marketed Products
4.17.1.1.1 Trimbow: Recent Developments
4.17.2 Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.17.2.1 Latest Developments Related to Key Pipeline Products
4.17.2.1.1 Bronchitol: Recent Development
4.17.2.1.2 CHF 6297: Recent Development
4.17.3 Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2019-2030
4.18 Pulmatrix: Company Overview & Analysis
4.18.1 Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.18.1.1 Latest Developments Related to Key Pipeline Products
4.18.1.1.1 Pur0200-Us: Recent Development
4.18.1.1.2 Pur1900: Recent Development
4.19 Verona Pharma Plc– Company Overview & Analysis
4.19.1 Verona Pharma Plc, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.19.1.1 Latest Development Related to The Pipeline Products
4.19.1.1.1 Rpl554: Recent Developments
4.19.2 Verona Pharma Plc -Asthma & COPD Market Forecast, 2019-2030
4.20 Alk-Abelló A/S– Company Overview & Analysis
4.20.1 Alk-Abelló A/S Marketed Asthma & COPD Products
4.20.2 Alk-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.20.2.1 Latest Developments Related to The Pipeline Products
4.20.2.1.1 Grazax: Recent Developments
4.20.3 Alk-Abelló A/S -Asthma & COPD Market Forecast, 2019-2030
4.21 Tff Pharmaceuticals, Inc.– Company Overview & Analysis
4.21.1 Tff Pharmaceuticals, Inc. Marketed Asthma & COPD Products
4.21.2 Tff Pharmaceuticals, Inc.: Asthma & COPD Products- R&D Pipeline & Future Outlook
4.21.2.1 Latest Developments Related to The Pipeline Products
4.21.2.1.1 Tff Triple Combination: Recent Developments
4.21.3 Tff Pharmaceuticals, Inc.-Asthma & COPD Market Forecast, 2019-2030
4.22 Respiratorius Ab – Company Overview & Analysis
4.22.1 Respiratorius Ab. Marketed Asthma & COPD Products
4.22.2 Respiratorius Ab: Asthma & COPD Products- R&D Pipeline & Future Outlook
4.22.2.1 Latest Developments Related to The Pipeline Products
4.22.2.1.1 Product: Recent Developments
4.22.3 Respiratorius Ab-Asthma & COPD Market Forecast, 2019-2030
4.23 Adamis Pharmaceuticals Corporation– Company Overview & Analysis
4.23.1 Adamis Pharmaceuticals Corporation. Marketed Asthma & COPD Products
4.23.2 Adamis Pharmaceuticals Corporation: Asthma & COPD Products- R&D Pipeline & Future Outlook
4.23.2.1 Latest Developments Related to the Pipeline Products
4.23.2.1.1 Product: Recent Developments
4.23.3 Adamis Pharmaceuticals Corporation. -Asthma & COPD Market Forecast, 2019-2030
4.24 Dimerix – Company Overview & Analysis
4.24.1 Dimerix Marketed Asthma & COPD Products
4.24.2 Dimerix: Asthma & COPD Products- R&D Pipeline & Future Outlook
4.24.2.1 Latest Developments Related to The Pipeline Products
4.24.2.1.1 Product: Recent Developments
4.24.3 Dimerix -Asthma & COPD Market Forecast, 2019-2030
4.25 Innoviva– Company Overview & Analysis
4.25.1 Innoviva. Marketed Asthma & COPD Products
4.25.1.1 Product: Recent Developments
4.25.2 Innoviva. -Asthma & COPD Market Forecast, 2019-2030
4.26 Mereo Biopharma Group Plc– Company Overview & Analysis
4.26.1 Mereo Biopharma Group Plc Marketed Asthma & COPD Products
4.26.2 Mereo Biopharma Group Plc: Asthma & COPD Products- R&D Pipeline & Future Outlook
4.26.2.1 Latest Developments Related to the Pipeline Products
4.26.2.1.1 Product: Recent Developments
4.26.3 Mereo Biopharma Group Plc -Asthma & COPD Market Forecast, 2019-2030
5 Conclusions
5.1 Asthma & COPD Products: A Maturing Market
5.2 The Global Asthma & COPD Companies Market In 2020-2030
5.3 Leading Asthma & COPD Companies
5.4 Global Asthma & COPD Products Market Forecast 2020-2030
5.5 The Future of the Asthma & COPD Products Market
5.5.1 Growth in Anti-Inflammatory and Combination Drugs
5.5.2 Personalised Medicine
5.5.3 Unmet needs in Asthma and COPD
5.6 Strategies for Growth in 2020-2030
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Advantages and Disadvantages of The Main Types of Asthma Inhalers
Table 2.2 E-Technology Based Inhalers
Table 3.1 Global Market Forecast: Revenues ($Bn), AGR (%) By Leading Companies, 2019-2030
Table 3.2 Leading Companies in Asthma & COPD Diseases
Table 3.3 Leading Asthma & COPD Companies: Revenues ($Bn) And Market Shares (%), 2019 And 2030
Table 4.1 Astrazeneca: Company Overview
Table 4.2 Astrazeneca: Products Portfolio
Table 4.3 Astrazeneca: Products Pipeline Portfolio
Table 4.4 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.5 Glaxosmithkline: Company Overview
Table 4.6 Glaxosmithkline: Products Portfolio
Table 4.7 Glaxosmithkline: Products Pipeline Portfolio
Table 4.8 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.9 Boehringer Ingelheim: Company Overview
Table 4.10 Boehringer Ingelheim: Products Portfolio
Table 4.11 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.12 Teva: Company Overview
Table 4.13 Teva: Products Portfolio
Table 4.14 Teva: Products Pipeline Portfolio
Table 4.15 Teva: Asthma & COPD Products Forecast: Revenue ($Bn), AGR(%), CAGR (%), 2019-2030
Table 4.16 Merck: Company Overview
Table 4.17 Merck: Products Portfolio
Table 4.18 Merck: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.19 Roche: Company Overview
Table 4.20 Roche: Products Portfolio
Table 4.21 Roche: Products Pipeline Portfolio
Table 4.22 Roche: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.23 Novartis: Company Overview
Table 4.24 Novartis: Products Portfolio
Table 4.25 Novartis: Products Pipeline Portfolio
Table 4.26 Novartis: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.27 Regeneron Pharmaceuticals (Sanofi): Company Overview
Table 4.28 Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio
Table 4.29 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.30 Mundipharma: Company Overview
Table 4.31 Mundipharma: Products Portfolio
Table 4.32 Mundipharma: Products Pipeline Portfolio
Table 4.33 Theravance Biopharma: Company Overview
Table 4.34 Theravance Biopharma: Products Portfolio
Table 4.35 Theravance Biopharma: Products Pipeline Portfolio
Table 4.36 Amphastar Pharmaceuticals: Company Overview
Table 4.37 Amphastar Pharmaceuticals: Products Pipeline Portfolio
Table 4.38 Cipla: Company Overview
Table 4.39 Cipla: Products Portfolio
Table 4.40 Sunovion Pharmaceuticals: Company Overview
Table 4.41 Sunovion Pharmaceuticals: Products Portfolio
Table 4.42 Sunovion: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.43 Circassia: Company Overview
Table 4.44 Circassia: Products Portfolio
Table 4.45 Circassia: Products Pipeline Portfolio
Table 4.46 Vectura Group: Company Overview
Table 4.47 Vectura Group: Products Portfolio
Table 4.48 Vectura Group: Products Pipeline Portfolio
Table 4.49 Lallemand Pharma Ag: Company Overview
Table 4.50 Lallemand Pharma Ag: Products Portfolio
Table 4.51 Lallemand Pharma Ag: Products Pipeline Portfolio
Table 4.52 Chiesi Farmaceutici S.P.A: Company Overview
Table 4.53 Chiesi Farmaceutici S.P.A: Products Portfolio
Table 4.54 Chiesi Farmaceutici S.P.A: Products Pipeline Portfolio
Table 4.55 Chiesi Farmaceutici S.P.A: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
Table 4.56 Pulmatrix: Company Overview
Table 4.57 Pulmatrix: Products Pipeline Portfolio
Table 4.58 Verona Pharma Plc: Company Overview
Table 4.59 Verona Pharma Plc: Products Pipeline Portfolio
Table 4.60 Alk-Abelló A/S: Company Overview
Table 4.61 Alk-Abelló A/S Products Portfolio
Table 4.62 Alk-Abelló A/S: Products Pipeline Portfolio
Table 4.60 Tff Pharmaceuticals, Inc.: Company Overview
Table 4.62 Tff Pharmaceuticals, Inc.: Products Pipeline Portfolio
Table 4.60 Respiratorius Ab: Company Overview
Table 4.62 Respiratorius Ab: Products Pipeline Portfolio
Table 4.63 Respiratorius Ab: Resp1000 Patent Portfolio
Table 4.63 Respiratorius Ab: Resp2000 Patent Portfolio
Table 4.60 Adamis Pharmaceuticals Corporation: Company Overview
Table 4.62 Adamis Pharmaceuticals Corporation: Products Pipeline Portfolio
Table 4.60 Dimerix: Company Overview
Table 4.62 Dimerix: Products Pipeline Portfolio
Table 4.60 Innoviva: Company Overview
Table 4.61 Innoviva Products Portfolio
Table 4.60 Mereo Biopharma Group Plc: Company Overview
Table 4.62 Mereo Biopharma Group Plc: Products Pipeline Portfolio
List of Figures
Figure 1.1 Global Asthma & COPD Companies Market Segmentation Overview, 2020-2030
Figure 2.1 Stepwise Approach to Treatment Of COPD
Figure 2.2 Stepwise Approach to Treatment Of Asthma
Figure 3.1 Global: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 3.2 Leading Asthma & COPD Drug Manufacturers: Revenue ($Bn), 2019
Figure 3.3 Leading Asthma & COPD Drug Manufacturers: Market Share (%), 2019
Figure 3.4 Leading Asthma & COPD Companies: Revenues ($Bn), 2030
Figure 3.5 Leading Asthma & COPD Companies: Market Shares (%), 2030
Figure 4.1 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.2 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.3 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.4 Teva: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.5 Merck: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.6 Roche: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.7 Novartis: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.8 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.9 Sunovion Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 4.10 Chiesi Farmaceutici Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
Figure 5.1 World Asthma & COPD Products Market Forecast: Revenues ($Bn), 2019-2030
Aerocrine (Circassia)
ALK-Abello A/S
American College of Chest Physicians (ACCP)
Amphastar Pharmaceuticals, Inc.
AstraZeneca
Boehringer Ingelheim
Chiesi Farmaceutici
Ciba-Geigy
Cipla
Committee for Medicinal Products for Human Use (CHMP)
Dainippon Sumitomo Pharma America, Inc.
Dermira Inc.
European Medicines Agency (EMA)
European Respiratory Society (ERS)
GlaxoSmithKline (GSK)
Glenmark
Hikma
Innovata plc
Innoviva, Inc.
Japanese Ministry of Health, Labour and Welfare
Lallemand Pharma International
Medicines and Healthcare products Regulatory Agency (MHRA)
Merck
Monitored Therapeutics, Inc. (MTI)
MundiPharma
Mylan
National Institute for Health and Care Excellence (NICE)
Novartis
Pulmatrix
Regeneron
Roche
Sandoz
Sanofi
Sepracor Inc.
Sorrento
Sunovion
Teva
Theravance Biopharma|Mylan Inc.
Torii
Vectura Group plc
Verona Pharma plc
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
